Page 120 - 《中国药房》2024年20期

（Suppl. 2）：69. [22] PUGLIESE D，PRIVITERA G，SCHEPIS T，et al. Drug-
[12] LAWRENCE R，KLINGS E S. Management of chronic related pneumonitis in patients receiving vedolizumab
eosinophilic pneumonia with mepolizumab[J]. Am J therapy for inflammatory bowel disease[J]. Clin Gastroen‐
Respir Crit Care Med，2019，199：A1522. terol Hepatol，2022，20（6）：e1483-e1487.
[13] MYC L A，GIRTON M R，STOLER M H，et al. Necro- [23] DULANEY D，DAVE P，WALSH S，et al. Noninfectious
biotic pulmonary nodules of Crohn’s disease in a patient pulmonary complications associated with anti-integrin
receiving vedolizumab[J]. Am J Respir Crit Care Med， therapy：a case report and systematic review of the litera‐
2019，199（1）：e1-e2. ture[J]. Inflamm Bowel Dis，2022，28（3）：479-483.
[14] DAVIDSON R，HERSHBERGER D. The rise of respira‐ [24] ZHANG J，LIU M H，GAO X，et al. Vedolizumab-
tory manifestations of inflammatory bowel disease：can associated diffuse interstitial lung disease in patients with
treatment be too selective? [J]. Chest，2019，156（4）： ulcerative colitis：a case report[J]. World J Clin Cases，
A1819. 2022，10（5）：1716-1722.
[15] AJMAL Z，CHUNG J，ZAHRA F T，et al. Necrobiotic pul‐ [25] CUCINOTTA U，DIPASQUALE V，COSTA S，et al.
monary nodules in a patient with Crohn’s disease recei- Vedolizumab-associated pulmonary manifestations in chi-
ving vedolizumab[J]. Chest，2020，158（4）：A2003-A2004. ldren with ulcerative colitis[J]. J Clin Pharm Ther，2022，
[16] DE BACKER E，BODE H，BAERT F. New-onset diffuse 47（2）：254-256.
parenchymal lung disease in a 52-year-old woman with [26] FARIA L M，OLIVEIRA M M，FARIA A A，et al. Late on‐
ulcerative colitis[J]. Gastroenterology，2020，158（3）： set vedolizumab-induced eosinophilic pneumonia in a pa‐
478-479. tient with ulcerative colitis[J]. Eur J Gastroenterol Hepa‐
[17] ABU SHTAYA A，COHEN S，KOGAN Y，et al. Crohn’s tol，2023，35（4）：513-514.
disease with atypical extra-intestinal manifestations deve- [27] LAMB C A，O’BYRNE S，KEIR M E，et al. Gut-
loping under treatment with vedolizumab[J]. Eur J Case selective integrin-targeted therapies for inflammatory
Rep Intern Med，2021，8（3）：002265. bowel disease[J]. J Crohns Colitis，2018，12（Suppl. 2）：
[18] SEDANO R，DHALIWAL I，RAMSEWAK D，et al. Drug- S653-S668.
induced lupus associated with vedolizumab in a patient [28] BRANDT E B，ZIMMERMANN N，MUNTEL E E，et al.
with Crohn’s disease[J]. Inflamm Bowel Dis，2021，27 The α4bβ7-integrin is dynamically expressed on murine
（4）：e47-e48. eosinophils and involved in eosinophil trafficking to the
[19] RIZOS E D，ANTONOGIANNAKI E M，CHATZIDAKIS intestine[J]. Clin Exp Allergy，2006，36（4）：543-553.
A，et al. Vedolizumab-induced acute interstitial lung injury [29] MASSART A，HUNT D P. Pulmonary manifestations of
in a 39-year-old male with ulcerative colitis[J]. Eur J inflammatory bowel disease[J]. Am J Med，2020，133（1）：
Gastroenterol Hepatol，2021，33（1S Suppl. 1）：e1057- 39-43.
e1059. [30] 王晨玉，黄元楷，席晓宇. 我国临床药师与医师协作概念
[20] PATEL P，OCHIENG P，SHETTY A. Another sequalae of 的探讨[J]. 中国药房，2023，34（4）：487-492.
COVID? Not so fast[J]. Am J Respir Crit Care Med， WANG C Y，HUANG Y K，XI X Y. Discussion on the
2022，205：A4565. concept of collaboration between clinical pharmacists and
[21] ZHU W W，ZHAO T H，WEI J，et al. Case report：eosino‐ physicians in China[J]. China Pharm，2023，34（4）：
philic pneumonia associated with vedolizumab therapy in 487-492.
a patient with ulcerative colitis[J]. Front Med，2022，9： （收稿日期：2024-03-21 修回日期：2024-08-27）
942237. （编辑：张元媛）

· 2558 · China Pharmacy 2024 Vol. 35 No. 20 中国药房 2024年第35卷第20期